The multi-organ influence of variants in NOD2 and CDKN2A are associated with the risk of cancers occurring in the colon, ovary, breast, lung, larynx, Non-Hodgkin lymphoma and melanoma [1–16]. Here, CDKN2A is linked to cancer.